Function and Clinical Significance of Platelet-Derived Microparticles

Nomura, Shosaku

doi:10.1007/bf02982082

Cited by 117 publications

(93 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PDMP were detected using a modification of the previously reported method. [4][5][6][7] An aliquot (10 ml) of platelet suspension (3 Â 10 8 /ml) was added to 100 ml of 2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulphonic acid (HEPES)-Tyrode's buffer containing 5 mmol/l ethylene glycol-bis-(2-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), and both intact and aggregated platelets were removed by centrifugation at 1000 g for 15 min to obtain a supernatant that only contained microparticles. Then washed intact platelets (10 ml, 3 Â 10 8 /ml) were added to the supernatant, and incubation with KMP-9 (a fluorescein isothiocyanate (FITC)-labelled monoclonal antibody for platelet glycoprotein (GP) IX was performed for 30 min in the dark at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…3,4 PDMP have procoagulant activity, and some studies have assessed the potential role of PDMP in diabetic complications. [4][5][6][7][8] Monocytes also can synthesize procoagulants, which are largely tissue factors, 9,10 and monocyte vesiculation is a possible mechanism for the dissemination of membrane-associated procoagulant activity. 11 We previously reported that a high level of monocyte-derived microparticles (MDMP) may be a marker of vasculopathy in diabetic patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

Nifedipine, a dihydropyridine calcium antagonist, improves endothelial function in patients with hypercholesterolaemia by enhancing nitric oxide (NO) activity, and increases endothelial NO bioavailability by antioxidant mechanisms. We administered a long-acting nifedipine formulation (controlled release (CR) nifedipine: 20 mg/day) to hypertensive patients for 6 months. There were no other changes of drug treatment during therapy with CR nifedipine. Clinical and biochemical data obtained before and after CR nifedipine administration were compared. All markers were measured by enzyme-linked immunosorbant assay. The levels of soluble markers (soluble CD40 ligand, soluble P-selectin, and soluble E-selectin), microparticles (MP) (platelet-derived MP, monocyte-derived MP, and endothelial cell-derived MP), and adiponectin differed between the control group and the hypertension group. The levels of these markers were also different in hypertensive patients with and without type 2 diabetes compared with the control group. In the hypertensive patients with type 2 diabetes, all markers except adiponectin decreased significantly after 3 months of CR nifedipine treatment. In contrast, markers were unchanged in the hypertensive patients without type 2 diabetes. Adiponectin was increased after 6 months of CR nifedipine treatment in hypertensive patients with type 2 diabetes. The effects of CR nifedipine on platelet/monocyte activation and adiponectin levels demonstrated in the present study indicate the potential effectiveness of calcium antagonist therapy for hypertensive patients with type 2 diabetes.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Platelet microparticles, released after activation, 29 have procoagulant effects, might promote platelet adhesion to the vessel wall, might promote thrombin generation, and are implicated in many disease processes, including the atherosclerotic complications of diabetes. 30 Although there are few reports of raised platelet microparticles in hypertension, they could play a role in thrombotic complications, being produced when platelets are exposed to increased shear force seen in hypertension.…”

Section: Evidence Of Platelet Activation In Hypertensionmentioning

confidence: 99%

Pharmacological Modulation of Platelet Function in Hypertension

2003

View full text Add to dashboard Cite

Abstract-Platelets exert a considerable influence on human morbidity and mortality. The rationale for their study in hypertension follows the observation that the major consequences of hypertension are stroke and myocardial infarction. However, the etiology of these consequences in hypertension is, paradoxically, not hemorrhagic (as might be expected from the effects of high blood pressure), but occlusive, with thrombus being the culprit lesion. Mechanisms of platelet activation include high shear force, activation of the renin-angiotensin system, endothelial changes, and the presence of comorbidity, such as atrial fibrillation. The treatment of high blood pressure brings about a reversal of the changes seen in the cell. This could be in part due to the direct effect of the drug on the megakaryocyte and/or the platelets themselves, or it might simply be due to the reduction in blood pressure. Some drugs, such as calcium channel antagonists and angiotensin II receptor blockers, however, might have direct effects on platelet biochemistry other than reducing blood pressure. Finally, antiplatelet drugs are becoming an important part of the management of high-risk hypertensives, which aim to minimize vascular complications. (Hypertension. 2003;42:1-7.)

show abstract

“…Our findings suggest that PDMPs may have a wide range of biological actions, including procoagulant, proinflammatory, and proatherogenic activities 7,37) in healthy individuals. Accumulating evidence indicates that PDMPs enhance the expression of cell adhesion molecules, recruit monocytes on the vascular wall, and induce the proliferation of smooth muscle cells 43,44) , thereby exerting pro-atherogenic activity 7,20,37,45) . The major factor leading to cellular cross-talk may be the ability of PDMPs to convey biological effectors.…”

Section: Discussionmentioning

confidence: 79%

“…P-selectin and CD40 ligand 6,7) . Progressive atherosclerosis induces the elevation of PDMPs via shear-induced platelet activation 8,9) .…”

mentioning

confidence: 99%

Plasma Level of Platelet-Derived Microparticles Is Associated with Coronary Heart Disease Risk Score in Healthy Men

Ueba

Nomura

Inami

et al. 2010

JAT

Self Cite

View full text Add to dashboard Cite

Aim:The aim of this study was to clarify the relationship between platelet-derived microparticles (PDMPs) and the Framingham 10-yr coronary heart disease (CHD) risk score. Methods: A cross-sectional study of healthy volunteers free of medication, and cardiovascular or cerebrovascular disease was conducted. The subjects were 190 Japanese men (median age 41). An ELISA kit and monoclonal antibodies against CD42b and CD42a (glycoprotein Ib and IX) were used. Results: PDMPs are correlated with platelet count, high sensitivity C-reactive protein (hsCRP), and diastolic blood pressure by multivariate analysis (R 2 0.316, p 0.001). Quartile range of PDMPs is significantly associated with the 10-yr CHD risk score after adjusting for age, platelet count, hsCRP, and hypertension (p 0.033) and for age, platelet count, hsCRP, and presence of metabolic syndrome (MS) (p 0.020). In individuals with a predicted 10-yr risk for CHD 8% (corresponding with the highest quartile), compared to those with a predicted 10-yr risk 8%, the odds ratio (OR), adjusted for age, platelet count, hsCRP, and hypertension, was 3.3 (1.2 8.9) and adjusted for age, platelet count, hsCRP, and MS, was 4.5 (1.6 11.8). The age-, platelet count-, hsCRP-and hypertensionadjusted OR for a 10-yr CHD risk score 8% was 0.8 (0.5 1.3) for hsCRP and 3.9 (1.6 9.4) for hypertension. The age-, platelet count-, hsCRP-and MS -adjusted OR for a 10-yr CHD risk score 8% was 0.7 (0.4 1.2) for hsCRP and 7.9 (2.6 24.5) for MS. Conclusion: Elevated PDMPs are associated with the 10-yr CHD risk score in healthy men. J Atheroscler Thromb, 2010; 17:342-349.

show abstract

Function and Clinical Significance of Platelet-Derived Microparticles

Cited by 117 publications

References 111 publications

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus

Pharmacological Modulation of Platelet Function in Hypertension

Plasma Level of Platelet-Derived Microparticles Is Associated with Coronary Heart Disease Risk Score in Healthy Men

Contact Info

Product

Resources

About